期刊文献+

大肠黏膜癌变过程中PGE_2,Bcl-2及Bax表达相关性 被引量:6

Expression of PGE_2, Bcl-2 and Bax in carcinogenesis of colorectal mucosa
下载PDF
导出
摘要 目的:探讨PGE2,Bcl-2及Bax在大肠黏膜癌变过程中表达相关性.方法:采用免疫组织化学DAB法检测了正常结肠黏膜15例、慢性结肠炎20例、大肠癌旁组织50例、腺瘤样息肉30例及大肠癌组织50例中PGE2,Bcl-2及Bax蛋白的表达.分析PGE2、Bcl-2及Bax的表达与各种临床病理特征的关系及三者的相关性.结果:PGE2在正常结肠黏膜,慢性结肠炎,大肠癌旁组织,腺瘤样息肉及大肠癌组织中的表达阳性率分别是6.67%,10.0%,40.0%,56.7%,90.0%,呈递增趋势.Bcl-2在5组中的表达阳性率分别为6.67%,10.0%,38.0%,46.7%,76.0%,呈递增趋势.Bax在5组中的表达阳性率分别为86.67%,75.0%,78.0%,76.7%,82.0%,五组之间阳性率比较均无显著性差异(P>0.05),但其阳性表达程度在正常组织,腺瘤样息肉,大肠癌三组之间呈递减趋势(P<0.05).3者在大肠癌中的表达与患者性别、年龄、肿块大小无明显差异(P>0.05).PGE2和Bcl-2、Bax和Bcl-2在大肠癌组织中阳性反应呈显著正相关(r=0.532,P<0.05;r=0.653.P<0.05).PGE2、Bcl-2及Bax在大肠癌高、中分化组中的表达率分别为100%,88.9%,85.2%,明显高于低分化组中的79.3%、60.9%、78.3%;在大肠癌Duke’sA,B期中Bcl-2表达却显著高于C,D期.结论:PGE2及Bcl-2在正常结肠黏膜、慢性结肠炎、大肠腺瘤样息肉、大肠癌组织中的表达均呈递增趋势,而Bax在正常结肠黏膜、大肠腺瘤样息肉、大肠癌组织中的阳性表达程度呈递减趋势提示PGE2及Bcl-2表达上调和Bax表达下调与大肠黏膜癌变过程有关.PGE2在大肠癌中的表达与肿瘤分化程度有关,Bcl-2在大肠癌中的表达与肿瘤分化程度、Duke’s分期有关.PGE2与Bcl-2的表达呈正相关. AIM: To investigate the expression of PGE2, Bcl-2 and Bax in the carcinogenesis of colorectal mucosa and the relationship between them. METHODS: The expression of PGE2, Bcl-2 and Bax were detected in 15 normal colorectal mucous membrane (NCM), 20 chronic colonitis (CHC), 30 colorectal adenoma (CAA), 50 colorectal cancer (CC)and 50 cancer adjacent (CAT) tissues by DAB immunohistochemical staining. The correlations among PGE2, Bcl-2 and Bax expression as well as the clinical and pathological characteristics were analyzed. RESULTS: The rates of PGE2 expression in NCM, CHC, CAT, CAA and CC tissues were 6.67%, 10%, 40%, 56.7% and 90% respectively and manifested an ascending trend. The rates of Bcl-2 expression in the five groups were 6.67%, 10%, 38%, 46.7%, and 76% respectively and also showed an ascending trend. The rates of Bax expression in the five groups was 86.67%, 75%, 78%, 76.7% and 82% respectively and there was no significant difference among the five groups (P>0.05). However, the positive degree in NCM, CA and CC group exhibited a descending trend (P<0.05). The expressions of PGE2, Bcl-2 and Bax in human CC were not associated with sex, age and the size of tumor (P>0.05). A positive correlation was noted be- tween expression of PGE2and Bcl-2 in CC tissue (r= 0.532, P<0.05). The same correlation also existed between Bax and Bcl-2 (r= 0.653, P<0.05). The rates of PGE2, Bcl-2 and Bax expression in highly and moderately differentiated CC were significantly higher than those in lowly differentiated one (100%, 88.9%, 85.2% vs 79.3%, 60.9%, 78.3%;P<0.05). The expression of Bcl-2 was significantly higher in Duke's A, B stage than that in Duke's C, D (90%, 77.8% vs 60%, 57.2%;P<0.05). CONCLUSION: The expression of PGE2 and Bcl-2 increases while that of Bax decreases with the occurrence and development of CC, which indicates that PGE2 and Bcl-2 play important roles in the carcinogenesis and development of CC. At the same time, there is a positive relationship between PGE2 and Bcl-2.
出处 《世界华人消化杂志》 CAS 北大核心 2005年第11期1305-1309,共5页 World Chinese Journal of Digestology
  • 相关文献

参考文献2

二级参考文献29

  • 1Wiley SR, Scheoley K, Smolak PJ, et al. Identification and characterization of a new member of the TNF family that induces apoptosis [J]. Immunity, 1995, 3 (6): 673 - 682.
  • 2Pitti RM, Marsters SA, Ruppert S, et al. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family [J]. J Biol Chem, 1996, 271:12687 - 12690.
  • 3Pan G, O'Rourke K, Chinnaiyan AM, et al. The receptor for the cytotoxic ligand TRAIL [J]. Science, 1997, 276:111 - 113.
  • 4Shin EC, Seong YR, Kim CH, et al. Human hepatocellular carcinoma cells resist to TRAIL-induced apoptosis, and the resistance is abolished by cisplatin [J]. Exp Mol Med,2002,31,34(2): 114- 122.
  • 5Pan G, Ni J, Wei YF, et al. An antagonist decoy receptor and a death domain-containing receptor for TRAIL [ J ]. Science, 1997,277:815 -818.
  • 6Kim Y, Suh N, Spore M, et al. An inducible pathway for degradation of FLIP protein sensitizes tumor cells to TRAIL-induced apoptosis [J] . J Biol Chem, 2002, 277(25):22320 - 22329.
  • 7Evdokiou A, Bouralexis S, Atkins GJ, et al. Chemotherapeutic agents sensitize osteogenic sarcoma cells, but not normal human bone cells, to Apo2L/TRAIL-induced apoptosis [Jl . Int J Cancer, 2002, 99(4): 491 - 504.
  • 8Lacour S, Hammann A, Wotawa A, et al. Anticancer agents sensitize tumor cells to tumor necrosis Factor-related apoptosis-inducing ligand-mediated caspase-8 activation and apoptosis [J]. Cancer Res, 2001,61:1645 - 1651.
  • 9Xiang H, Fox JA, Totpal K, et al. Enhanced tumor killing by Apo2L/TRAIL and CPT-11 co-treatment is associated with p21 cleavage and differential regulation of Apo2L/TRAIL ligand and its receptors [J]. Oncogene, 2002, 21:3611 - 3619.
  • 10Hernandez A, Wang QD, Scbwartz SA, et al. Sensitization of human colon cancer cells to TRAIL-mediated apoptosis [J]. J Gastrointestinal Surg, 2001,5:56 - 65.

共引文献2

同被引文献65

引证文献6

二级引证文献40

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部